Collecting samples to study why mavacamten works differently for people with hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study collects blood samples from people with obstructive hypertrophic cardiomyopathy (a type of heart muscle disease) to explore how genetics and other factors affect how well the drug mavacamten works. It may help doctors better understand who benefits most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a diagnosis of obstructive hypertrophic cardiomyopathy (a thickened heart muscle that blocks blood flow) with a specific heart pressure gradient of 50 mmHg or more at rest or with activity.
- You have heart symptoms like shortness of breath or chest pain (NYHA class II or III) that continue despite taking standard medications like beta-blockers or calcium channel blockers.
- Your heart's pumping ability (ejection fraction) is 55% or higher before starting mavacamten.
- You are either already taking mavacamten or about to start it, and have had a genetic test for CYP2C19 (a liver enzyme that affects drug breakdown).
- You have health insurance and agree to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This trial tests whether a person's genetic makeup can predict how well they respond to the drug mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle is thickened and blocks blood flow.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.